Axonal Degeneration in LRRK2 Parkinson?s Disease
LRRK2 帕金森病中的轴突变性
基本信息
- 批准号:8212966
- 负责人:
- 金额:$ 39.24万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-09-30 至 2012-08-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Parkinson's disease (PD) is the second most common neurodegenerative disease. Mutations in Leucine-rich-repeat-kinase 2 (LRRK2), the newly identified causative gene for PARK8 type PD with autosomal dominant inheritance, are the most prevalent genetic causes in both familial and sporadic PD. Therefore it is important to understand the mechanisms of LRRK2 mediated pathogenesis. We have generated the first transgenic mouse model for LRRK2 that recapitulated robust motor behavioral, neurochemical and pathological features of PD. These mice develop an age-dependent progressive decrease in motor activity that is responsive to treatment with levodopa. At the level of pathology, the early and most robust phenotype is the axonopathy of the nigrostriatal dopaminergic projection, accompanied by hyperphosphorylated tau. Therefore, among all the aspects of LRRK2 induced pathogenesis, the tau-mediated axonal degeneration is particularly important and worth a major effort of investigation. We will address important questions at molecular, cellular and animal model levels. Hypothesis 1: At the molecular level, LRRK2 induces tau hyperphosphorylation that mediates the pathogenic effects. Specific Aim 1: To confirm that tau is an integral component of mutant LRRK2 kinase signaling. Hypothesis 2: At the cellular level, tau mediated axonal degeneration is a critical aspect of LRRK2 PD. Specific Aim 2: To investigate whether LRRK2-induced tau hyperphosphorylation causes axonal pathology in primary neuronal cell cultures. Hypothesis 3. At the organismal level, tau-mediated axonopathy leads to dopaminergic neuronal degeneration and progressive motor deficits. Specifc Aim 3: To test the interaction of tau and LRRK2 in genetic mouse models. This set of studies will identify the molecules and the pathways in LRRK2 pathogenesis. This is not only important from a scientific point, but also critical for the therapeutic development that directly addresses a major public health issue. PUBLIC HEALTH RELEVANCE: Parkinson's disease (PD) is the second most common neurodegenerative disease. Mutations in Leucine-rich-repeat-kinase 2 (LRRK2) are the most important genetic causes in PD. Therefore the understanding of the LRRK2 pathogenic mechanisms is not only important from a scientific point, but also critical for the therapeutic development that directly addresses a major public health issue.
描述(由申请人提供):帕金森病(PD)是第二常见的神经退行性疾病。富含亮氨酸重复序列激酶2(Leucine-rich-repeat-kinase 2,LRRK 2)是新近发现的PARK 8型PD的致病基因,具有常染色体显性遗传,是家族性和散发性PD中最常见的遗传原因。因此,了解LRRK 2介导的发病机制是重要的。我们已经产生了第一个LRRK 2转基因小鼠模型,该模型概括了PD的强大运动行为,神经化学和病理学特征。这些小鼠出现对左旋多巴治疗有反应的运动活动的年龄依赖性进行性降低。在病理学水平上,早期和最稳健的表型是黑质纹状体多巴胺能投射的轴突病,伴有过度磷酸化的tau蛋白。因此,在LRRK 2诱导的发病机制的所有方面中,tau介导的轴突变性是特别重要的,值得研究的主要努力。我们将在分子,细胞和动物模型水平上解决重要问题。假设1:在分子水平上,LRRK 2诱导tau蛋白过度磷酸化,介导致病作用。具体目的1:确认tau蛋白是突变型LRRK 2激酶信号传导的组成部分。假设2:在细胞水平,tau介导的轴突变性是LRRK 2 PD的关键方面。具体目标2:研究LRRK 2诱导的tau蛋白过度磷酸化是否会导致原代神经元细胞培养物中的轴突病理学。假设3.在生物体水平,tau介导的轴突病导致多巴胺能神经元变性和进行性运动缺陷。具体目的3:在遗传小鼠模型中测试tau和LRRK 2的相互作用。这组研究将确定LRRK 2发病机制中的分子和途径。这不仅从科学角度来看很重要,而且对于直接解决重大公共卫生问题的治疗发展也至关重要。公共卫生相关性:帕金森病(PD)是第二常见的神经退行性疾病。富含亮氨酸重复序列激酶2(LRRK 2)的突变是PD最重要的遗传原因。因此,对LRRK 2致病机制的理解不仅从科学角度来看很重要,而且对于直接解决重大公共卫生问题的治疗开发也至关重要。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Mouse models for LRRK2 Parkinson's disease.
- DOI:10.1016/s1353-8020(11)70058-x
- 发表时间:2012
- 期刊:
- 影响因子:4.1
- 作者:Qing Xu;Sushila A. Shenoy;Chenjian Li
- 通讯作者:Qing Xu;Sushila A. Shenoy;Chenjian Li
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHENJIAN LI其他文献
CHENJIAN LI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHENJIAN LI', 18)}}的其他基金
Axonal Degeneration in LRRK2 Parkinson?s Disease
LRRK2 帕金森病中的轴突变性
- 批准号:
7698560 - 财政年份:2009
- 资助金额:
$ 39.24万 - 项目类别:
Analyze mouse and cell culture models for PINK1 related Parkinson's disease
分析 PINK1 相关帕金森病的小鼠和细胞培养模型
- 批准号:
7579042 - 财政年份:2007
- 资助金额:
$ 39.24万 - 项目类别:
Analyze mouse and cell culture models for PINK1 related Parkinson's disease
分析 PINK1 相关帕金森病的小鼠和细胞培养模型
- 批准号:
7775008 - 财政年份:2007
- 资助金额:
$ 39.24万 - 项目类别:
Analyze mouse and cell culture models for PINK1 related Parkinson's disease
分析 PINK1 相关帕金森病的小鼠和细胞培养模型
- 批准号:
8044109 - 财政年份:2007
- 资助金额:
$ 39.24万 - 项目类别:
Analyze mouse and cell culture models for PINK1 related Parkinson's disease
分析 PINK1 相关帕金森病的小鼠和细胞培养模型
- 批准号:
7259816 - 财政年份:2007
- 资助金额:
$ 39.24万 - 项目类别:
Analyze mouse and cell culture models for PINK1 related Parkinson's disease
分析 PINK1 相关帕金森病的小鼠和细胞培养模型
- 批准号:
7383174 - 财政年份:2007
- 资助金额:
$ 39.24万 - 项目类别:
Analyze mouse and cell culture models for PINK1 related Parkinson's disease
分析 PINK1 相关帕金森病的小鼠和细胞培养模型
- 批准号:
7911486 - 财政年份:2007
- 资助金额:
$ 39.24万 - 项目类别:
Mouse Models And LRRK2 Kinase Substrates for Park8-Parkinson's Disease
Park8-帕金森病的小鼠模型和 LRRK2 激酶底物
- 批准号:
7134169 - 财政年份:2006
- 资助金额:
$ 39.24万 - 项目类别:
Mouse Models And LRRK2 Kinase Substrates for Park8-Parkinson's Disease
Park8-帕金森病的小鼠模型和 LRRK2 激酶底物
- 批准号:
7273867 - 财政年份:2006
- 资助金额:
$ 39.24万 - 项目类别:
MOLECULAR STUDY OF ESTROGEN INDUCED SYNAPTOGENESIS
雌激素诱导的突触发生的分子研究
- 批准号:
2421309 - 财政年份:1998
- 资助金额:
$ 39.24万 - 项目类别:
相似海外基金
I(eye)-SCREEN: A real-world AI-based infrastructure for screening and prediction of progression in age-related macular degeneration (AMD) providing accessible shared care
I(eye)-SCREEN:基于人工智能的现实基础设施,用于筛查和预测年龄相关性黄斑变性 (AMD) 的进展,提供可及的共享护理
- 批准号:
10102692 - 财政年份:2024
- 资助金额:
$ 39.24万 - 项目类别:
EU-Funded
Targeting axonal transport regulation by neurotrophic factors to treat peripheral nerve degeneration
通过神经营养因子调节轴突运输来治疗周围神经变性
- 批准号:
MR/Y010949/1 - 财政年份:2024
- 资助金额:
$ 39.24万 - 项目类别:
Fellowship
CAREER: Biomechanical Characterization of Periventricular White Matter and its Age-related Degeneration
职业:脑室周围白质的生物力学特征及其与年龄相关的变性
- 批准号:
2337739 - 财政年份:2024
- 资助金额:
$ 39.24万 - 项目类别:
Standard Grant
Mechanisms of accelerated calcification and structural degeneration of implantable biomaterials in pediatric cardiac surgery
小儿心脏手术中植入生物材料加速钙化和结构退化的机制
- 批准号:
10655959 - 财政年份:2023
- 资助金额:
$ 39.24万 - 项目类别:
Interrogating a white matter degeneration-specific astrocyte reactivity state and its role in governing repair-associated microglia specification and function.
询问白质变性特异性星形胶质细胞反应状态及其在控制修复相关小胶质细胞规格和功能中的作用。
- 批准号:
10660874 - 财政年份:2023
- 资助金额:
$ 39.24万 - 项目类别:
Relaxivity Contrast Imaging as Biomarker of Muscle Degeneration in ALS
弛豫对比成像作为 ALS 肌肉退化的生物标志物
- 批准号:
10783525 - 财政年份:2023
- 资助金额:
$ 39.24万 - 项目类别:
Pathophysiology and prevention of degeneration of heterograft biomaterials due to advanced glycation end products and serum protein infiltration
由于晚期糖基化终产物和血清蛋白浸润导致异种移植生物材料变性的病理生理学和预防
- 批准号:
10679910 - 财政年份:2023
- 资助金额:
$ 39.24万 - 项目类别:
The impact of age-related vitreous degeneration and vitreous replacement on scleral biomechanics: a novel mechanism and treatment target for glaucoma
年龄相关性玻璃体变性和玻璃体置换对巩膜生物力学的影响:青光眼的新机制和治疗目标
- 批准号:
10647522 - 财政年份:2023
- 资助金额:
$ 39.24万 - 项目类别:
Cellular mechanisms for the degeneration and aging of human rotator cuff tears
人类肩袖撕裂变性和衰老的细胞机制
- 批准号:
10648672 - 财政年份:2023
- 资助金额:
$ 39.24万 - 项目类别:
Common mechanistic biomarkers of vascular and neuro-degeneration
血管和神经变性的常见机制生物标志物
- 批准号:
10567120 - 财政年份:2023
- 资助金额:
$ 39.24万 - 项目类别: